Researchers employed a specialized brain imaging technique to identify a potential biomarker and therapeutic target for Long COVID. More than four years after the onset of the COVID-19 pandemic, scientists are still working to fully understand the lingering effects of infection with SARS-CoV-2. O
  • jqubed@lemmy.worldEnglish
    29·
    2 days ago

    As explained in their paper, published in Brain Communications on October 1, 2025, the team hypothesized that patients with brain fog might exhibit disrupted expression of AMPA receptors (AMPARs)—key molecules for memory and learning—based on prior research into psychiatric and neurological disorders such as depression, bipolar disorder, schizophrenia, and dementia. Thus, they used a novel method called [11C]K-2 AMPAR PET imaging to directly visualize and quantify the density of AMPARs in the living human brain.

    By comparing imaging data from 30 patients with Long COVID to 80 healthy individuals, the researchers found a notable and widespread increase in the density of AMPARs across the brains of patients. This elevated receptor density was directly correlated with the severity of their cognitive impairment, suggesting a clear link between these molecular changes and the symptoms. Additionally, the concentrations of various inflammatory markers were also correlated with AMPAR levels, indicating a possible interaction between inflammation and receptor expression.